ArticleFrontiers in immunology2026
The diagnostic accuracy of CC chemokine ligand 23 for Kawasaki disease.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Kawasaki Disease (KD) is an acute inflammatory disease that primarily affects children. Without timely treatment, it may lead to severe cardiovascular complications. Currently, the lack of specific biomarkers complicates its early diagnosis. Methods: This study focuses on investigating the diagnostic value of C-C motif chemokine ligand 23 (CCL23) protein in distinguishing KD from other similar diseases through gene expression profiling analysis and biomarker detection. Firstly, methods such as differentially expressed genes (DEGs) analysis, protein-protein interaction (PPI) network construction, and pathway enrichment analysis are employed to identify relevant Hub genes. Subsequently, Western blot technology is used to detect the expression of CCL23 protein in plasma, so as to externally validate the diagnostic value of the aforementioned relevant Hub genes in differentiating Kawasaki disease from other similar diseases. Results: We identified 11 significant hub genes and found that the concentration of CCL23 in the KD group was significantly higher than that in the febrile control group and the healthy control group. Further receiver operating characteristic (ROC) analysis showed that CCL23 exhibited good sensitivity and specificity in distinguishing Kawasaki Disease from other diseases. Meanwhile, pathway enrichment analysis revealed that CCL23 was upregulated in the cytokine-cytokine receptor interaction pathway, suggesting that it may play an important role in immune-inflammatory responses. Conclusions: Although this study has limitations such as insufficient sample size and lack of long-term follow-up, the results provide new insights into CCL23 as a potential biomarker for KD. Future studies should further validate these findings and explore their application in clinical practice to improve the early diagnosis rate of KD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.